Sayre Therapeutics commercializes niche pharmaceuticals, medical devices, and molecular diagnostics specifically for oncology and immunology, focusing on small molecules, recombinant proteins, and monoclonal antibodies. The company addresses the high unmet medical needs in South Asia by facilitating local clinical trials and regulatory pathways for novel treatments, ultimately improving patient outcomes in cancer care.
Funding
$9.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACFounders
Product
Problem
Patients in South Asia often lack access to advanced pharmaceutical treatments, medical devices, and molecular diagnostics for oncology and immunology due to regulatory hurdles and the need for local clinical trials. This results in unmet medical needs and suboptimal outcomes for those battling cancer and immunological disorders.
Solution
Sayre Therapeutics addresses this gap by accelerating the introduction of healthcare innovations to South Asia, focusing on niche products and orphan medications. The company specializes in facilitating local clinical trials and navigating regulatory pathways for novel treatments, including small molecules, recombinant proteins, and monoclonal antibodies. Sayre co-invests in clinical studies, designs trials tailored to the unique ethnic profile of the South Asian population, and incorporates health-economics and quality-of-life parameters. By simplifying the regulatory landscape and commercializing high-value solutions, Sayre Therapeutics aims to improve patient outcomes in oncology and immunology.
Target Audience
The primary target audience includes oncologists, rheumatologists, and patients in South Asia who require access to advanced treatments and diagnostics for cancer and immunological disorders.
Features
- Co-development of novel assets with potential licensors
- Expertise in conducting clinical studies tailored for the South Asian population, considering ethnic profiles and customization of therapies
- Streamlined regulatory pathways for novel drugs, drug-delivery devices, and companion diagnostics in India and other South Asian countries
- Focus on niche products and orphan medications with high unmet needs
- Special Access Programs to make unlicensed medicines available
- Commercialization of proprietary and niche brands through scientific brand promotion